NCT05833321 Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer
| NCT ID | NCT05833321 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Metropole Savoie |
| Condition | Ovarian Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2022-11-20 |
| Primary Completion | 2025-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 75 participants in total. It began in 2022-11-20 with a primary completion date of 2025-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective monocentric study, non-randomized of the detection of sarcopenia in clinical practice in patients with ovarian or endometrial cancer requiring systemic oncological treatment. main question : Identify the criteria correlated with the presence of sarcopenia (defined by the measurement of the IMS by the CT-X method in L3) among the impedancemetry and the HAS malnutrition criteria. Data collection will be done at 6 months, 12 months after the date of inclusion.
Eligibility Criteria
Inclusion Criteria: * Patients at least 18 years old * Patient presenting with a diagnosis of cancer of ovarian origin with an indication for chemotherapy * Patient with a diagnosis of endometrial cancer with an indication for chemotherapy * Patient with no diagnosis of other types of cancer in the previous five years * Collection of consent * Patient affiliated to a Social Security scheme Exclusion Criteria: * Patient with cancer of ovarian origin not requiring chemotherapy treatment * Patient with endometrial cancer not requiring chemotherapy treatment * Discovery of an intercurrent cancer other than skin or cervix cancers. * Patient wearing a Pace maker
Contact & Investigator
fillon aurélie
PRINCIPAL INVESTIGATOR
Centre Hospitalier Metropole Savoie
Frequently Asked Questions
Who can join the NCT05833321 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Ovarian Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05833321 currently recruiting?
Yes, NCT05833321 is actively recruiting participants. Contact the research team at florence.jego@ch-metropole-savoie.fr for enrollment information.
Where is the NCT05833321 trial being conducted?
This trial is being conducted at Chambéry, France.
Who is sponsoring the NCT05833321 clinical trial?
NCT05833321 is sponsored by Centre Hospitalier Metropole Savoie. The principal investigator is fillon aurélie at Centre Hospitalier Metropole Savoie. The trial plans to enroll 75 participants.